Literature DB >> 1856931

Elevated plasma chromogranin-A concentrations in prostatic carcinoma.

D Kadmon1, T C Thompson, G R Lynch, P T Scardino.   

Abstract

Chromogranin-A is considered a sensitive immunohistochemical tissue marker in neuroendocrine prostatic carcinoma. We report that the plasma chromogranin-A level was elevated in 48% of 25 patients with stage D2 prostate cancer, and suggest that this marker can be used to monitor the clinical course of these patients.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1856931     DOI： 10.1016/s0022-5347(17)37793-5

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  16 in total

1.  Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases.

Authors:  T L Wu; C P Chang; K C Tsao; C F Sun; J T Wu
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy.

Authors:  J T Wu; T L Wu; C P Chang; K C Tsao; C F Sun
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

3.  Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.

Authors:  Mark Kidd; Irvin M Modlin; Shrikant M Mane; Robert L Camp; Michael D Shapiro
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells.

Authors:  E M Garabedian; P A Humphrey; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.

Authors:  J T Wu; M E Astill; G H Liu; R A Stephenson
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

6.  Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.

Authors:  S S Jeetle; G Fisher; Z H Yang; E Stankiewicz; H Møller; C S Cooper; J Cuzick; D M Berney
Journal:  Virchows Arch       Date:  2012-07-06       Impact factor: 4.064

7.  Metastatic prostate cancer with normal level of serum prostate-specific antigen.

Authors:  R Nishio; Y Furuya; O Nagakawa; H Fuse
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

8.  Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.

Authors:  Y J Bang; F Pirnia; W G Fang; W K Kang; O Sartor; L Whitesell; M J Ha; M Tsokos; M D Sheahan; P Nguyen; W T Niklinski; C E Myers; J B Trepel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

9.  A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.

Authors:  Primo N Lara; Jeff Longmate; Christopher P Evans; David I Quinn; Przemyslaw Twardowski; Gurkamal Chatta; Edwin Posadas; Walter Stadler; David R Gandara
Journal:  Anticancer Drugs       Date:  2009-03       Impact factor: 2.248

10.  Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.

Authors:  I Kraljić; K Kovacić; M Tarle
Journal:  Urol Res       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.